Can weight-loss drugs and hormones make endometrial cancer surgery safer for obese women?

NCT ID NCT07462663

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a 28- to 54-week program of weight-loss medication (semaglutide), a hormone-releasing IUD, diet, and exercise is safe and feasible before surgery in women with early endometrial cancer and a BMI of 40 or higher. Eighty participants will be randomly assigned to either immediate surgery or the pre-surgery program. The goal is to see if the program reduces surgical risks without allowing the cancer to progress.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Semaglutide (weight-loss drug) and levonorgestrel IUD (hormonal device)
What this could lead to
If it works, this could point toward a safer, less invasive way to prepare for surgery in women with early endometrial cancer and severe obesity, potentially reducing surgical risks.
What could go wrong
This is a small pilot study (80 people) testing feasibility, not effectiveness. The pre-surgery delay could allow tumor progression, and the weight-loss drug may cause side effects like nausea or gastrointestinal issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATYPICAL ENDOMETRIAL HYPERPLASIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

More trials for these conditions

Other studies related to the condition(s) this trial covers.